Aging and the proteome, or How to die young at a very old age
Age is the biggest risk factor for a number of chronic diseases. While genetic changes across lifespan are limited, a recent study by Benoit Lehallier and Nir Barzilai demonstrated that the proteome undergoes measurable waves of change that reflect distinct biological pathways associated with age-linked disease. The study identified age-related patterns in ~3,000 proteins across >4,000 healthy individuals between the ages of 20 and 95 using the SomaScan® Proteomics Platform.
In this webinar, Lehallier and Barzilai discuss the findings of their Nature Medicine paper “Undulating changes in human plasma proteome profiles across the lifespan” and present new data exploring how probing the proteome can help us to separate chronological age from biological age.
Topics covered include:
- How circulating proteins can be used to predict age and relative health
- How the speed and timing of biological aging has changed over time
- Proteomic signatures of frailty
- Sex-related differences in proteome stability
- The proteome in descendants of centenarians
- Targeting aging based on protein signatures
Benoit Lehallier, PhD
Instructor in Neurology, Stanford University
Dr. Lehallier is a researcher and instructor in the department of Neurology and Neurosciences at Stanford University. Before joining Stanford, Benoit got his PhD in neuroscience from the French National Institute of Agriculture where he studied processing of odors in deep brain regions using MRI. As a postdoc at Roche, he collaborated with researchers at Stanford to identify novel fluid biomarkers of Alzheimer’s Disease. A biostatician by training, Benoit is now using multi-omics approaches to explore aging and aging-related disease in collaboration with Tony Wyss-Coray’s lab at Stanford.
Nir Barzilai, MD
Director, Institute for Aging Research, Albert Einstein College of Medicine
Dr. Barzilai is a chaired Professor of Medicine and Genetics and Director of the biggest center in the world to study the biology of aging and the principal investigator of the Einstein Nathan Shock Center and the Glenn Center. He is the recipient of an NIH Merit Award aiming to extend the healthy life span in rodents by biological interventions. He also studies families of centenarians that have provided genetic/biological insights on the protection against aging. Several drugs are developed based, in part, on these paradigm-changing studies. He is the author of over 270 peer-reviewed papers and a recipient of numerous prestigious awards, including the recipient of the 2010 Irving S. Wright Award of Distinction in Aging Research and is the 2018 recipient of the IPSEN Longevity award. He is leading the TAME (Targeting/Taming Aging with Metformin) multi central study to prove that concept that multi morbidities of aging can be delayed in humans and change the FDA indications to allow for next generation interventions. He is a founder of CohBar Inc. (now public company) and Medical Advisor for Life Biosciences. He is on the board of AFAR and a founding member of the Academy for Lifespan and Health span. He co-founded CohBar He has been featured in major papers, TV program and documentaries (TEDx and TEDMED) and has been consulting or presented the promise for targeting aging at The Singapore Prime Minister Office, several International Banks, The Vatican, Pepsico, Milkin Institute, The Economist and Wired Magazine.
WebinarUsing non-hypothesized based approaches for biomarker development
Current biomarkers are only moderately predictive in identifying individuals with mild traumatic brain injury or concussion. Therefore, more accurate diagnostic markers are needed for sport-related concussion (SRC).
WebinarAssessment of variability and normalization methods using the plasma 7K SomaScan® Assay v4.1
In this webinar, the speakers present the largest technical assessment of this platform to date based on a study of 2,050 samples across 22 plates.
WebinarThe proteomics of aging: how technology is advancing research
Please join us to hear four experts discuss the present challenges and opportunities for proteomics in aging research: Eric Morgen, COO of BioAge Labs; Paola Sebastiani, faculty biostatistician at Tufts Medical Center and PI on the Longevity Consortium; Birgit Schilling, associate professor, Buck Institute for Research on Aging; and Alessandro Ori, group leader at the Leibniz Institute on Aging.